<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137055</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP0678-19-01</org_study_id>
    <nct_id>NCT04137055</nct_id>
  </id_info>
  <brief_title>Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP0678 and the Effect of Food on ZSP0678 Pharmacokinetics in Chinese Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating&#xD;
      single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678&#xD;
      on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed&#xD;
      condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts&#xD;
      (Ascending single dose, multiple dose and food effect). Participants will receive either&#xD;
      ZSP0678 or placebo .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events (AEs) and Serious Adverse Events(SAE) following oral doses of ZSP0678 and placebo.</measure>
    <time_frame>SAD Group: Up to 5 days, MAD: Up to 18 days, FE group: Up to11 days after first dose ]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>The time after dosing when Cmax occurs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>t1/2 is defined as the time to decline half of the drug concentration in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf（AUC0-∞）</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>Area under the curve extrapolated until time is infinity (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast（AUC0-t）</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>λz</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CLr</measure>
    <time_frame>UP to 5, 18, 11 days for SAD, MAD, FE part respectively</time_frame>
    <description>CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose plasma PK parameter: Rac of ZSP0678 at steady state</measure>
    <time_frame>UP to 18 days.</time_frame>
    <description>Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose plasma PK parameter: DF of ZSP0678 at steady state</measure>
    <time_frame>UP to 18 days.</time_frame>
    <description>DF is defined as the percentage of fluctuation in steady state is 100 * (Cmax, ss - Cmin, ss)/Cavg, ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose plasma PK parameter: Cmin of ZSP0678 at steady state</measure>
    <time_frame>UP to 18 days.</time_frame>
    <description>Cmin is defined as the minimum observed concentration of drug in plasma at steady state.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>ZSP0678-10mg (single dose)-Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-30mg (single dose)-Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-60mg (single dose)-Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-120mg (single dose)-Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-180mg (single dose)-Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-240mg (single dose)-Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678-320mg (single dose)-Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678 (food effect)-Cohort FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.&#xD;
Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.&#xD;
Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678 Dose1 (multiple doses)-Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2&amp;3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678 Dose2 (multiple doses)-Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3&amp;4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP0678 Dose3 (multiple doses)-Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4&amp;5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-10mg</intervention_name>
    <description>ZSP0678 tablet administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-10mg (single dose)-Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-30mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-30mg (single dose)-Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-60mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-60mg (single dose)-Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-120mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-120mg (single dose)-Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-180mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-180mg (single dose)-Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-240mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-240mg (single dose)-Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-320mg</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted condition</description>
    <arm_group_label>ZSP0678-320mg (single dose)-Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678</intervention_name>
    <description>ZSP0678 tablets administered orally under fasted or fed condition</description>
    <arm_group_label>ZSP0678 (food effect)-Cohort FE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-Dose 1</intervention_name>
    <description>ZSP0678 tablets administered orally once daily for 14 Days</description>
    <arm_group_label>ZSP0678 Dose1 (multiple doses)-Cohort 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-Dose 2</intervention_name>
    <description>ZSP0678 tablets administered orally once daily for 14 Days</description>
    <arm_group_label>ZSP0678 Dose2 (multiple doses)-Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678-Dose 3</intervention_name>
    <description>ZSP0678 tablets administered orally once daily for 14 Days</description>
    <arm_group_label>ZSP0678 Dose3 (multiple doses)-Cohort 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP0678 Placebo</intervention_name>
    <description>Participants will receive placebo matching to ZSP0678 orally.</description>
    <arm_group_label>ZSP0678 (food effect)-Cohort FE</arm_group_label>
    <arm_group_label>ZSP0678 Dose1 (multiple doses)-Cohort 8</arm_group_label>
    <arm_group_label>ZSP0678 Dose2 (multiple doses)-Cohort 9</arm_group_label>
    <arm_group_label>ZSP0678 Dose3 (multiple doses)-Cohort 10</arm_group_label>
    <arm_group_label>ZSP0678-10mg (single dose)-Cohort 1</arm_group_label>
    <arm_group_label>ZSP0678-120mg (single dose)-Cohort 4</arm_group_label>
    <arm_group_label>ZSP0678-180mg (single dose)-Cohort 5</arm_group_label>
    <arm_group_label>ZSP0678-240mg (single dose)-Cohort 6</arm_group_label>
    <arm_group_label>ZSP0678-30mg (single dose)-Cohort 2</arm_group_label>
    <arm_group_label>ZSP0678-320mg (single dose)-Cohort 7</arm_group_label>
    <arm_group_label>ZSP0678-60mg (single dose)-Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are required to meet the following criteria in order to be included in the&#xD;
             trial:&#xD;
&#xD;
               1. Signature signed informed consent before the trial, and fully understood the&#xD;
                  content, process and possible adverse reactions.&#xD;
&#xD;
               2. Subjects must be willing and able to complete the research according to the&#xD;
                  experimental protocol.&#xD;
&#xD;
               3. Subjects (including partners) are willing to take effective contraceptive&#xD;
                  measures and have no pregnancy plan during the whole study period until 6 months&#xD;
                  after drug withdrawal.&#xD;
&#xD;
               4. Male and female subjects aged 18-50 (including 18 and 50)&#xD;
&#xD;
               5. Body weight of male subjects should not be less than 50kg and that of female&#xD;
                  subjects should not be less than 45kg.Body mass index (BMI) = weight (kg)/height&#xD;
                  2 (m2), the range of 19~26kg/m2 (including the critical value);&#xD;
&#xD;
               6. Physical condition:No significant abnormalities in medical history, including&#xD;
                  cardiovascular system, liver, kidneys, gastrointestinal system, neural system,&#xD;
                  respiratory system (eg.asthma,asthma induced by exercise,chronic obstructive&#xD;
                  pulmonary disease), mental, metabolism, etc.&#xD;
&#xD;
               7. Subjects in general good health or No significant abnormalities in the opinion of&#xD;
                  the investigator as determined by vital signs and a physical examination.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. Allergic constitution (allergic to many drugs, especially to ingredients similar&#xD;
                  to the test drug and food)&#xD;
&#xD;
               2. The average daily smoking are more than 5 cigarettes within 3 months prior to&#xD;
                  screening.&#xD;
&#xD;
               3. Known history of drug or alcohol abuse.(defined as consumption of more than 30g&#xD;
                  of ethanol a day for male and more than 20 g for female )&#xD;
&#xD;
               4. Subjects who donated blood or bleeding profusely(&gt; 400 mL)in the 3 months&#xD;
                  preceding study screening.&#xD;
&#xD;
               5. History of dysphagia or any gastrointestinal illness that affects drug&#xD;
                  absorption, including a history of frequent nausea or vomiting from any cause,&#xD;
                  irregular gastrointestinal motility, such as habitual diarrhea, constipation, or&#xD;
                  irritable bowel syndrome.&#xD;
&#xD;
               6. History or presence of any disease or condition known to increase the risk of&#xD;
                  bleeding, eg.acute gastritis, duodenal ulcer, etc.&#xD;
&#xD;
               7. Participated in another clinical research study and received any investigational&#xD;
                  products within 3 months prior to dosing.&#xD;
&#xD;
               8. Use of any prescription or over-the-counter (OTC) medications, vitamins and&#xD;
                  herbal within 14 days prior to screening.&#xD;
&#xD;
               9. History of having any special food(including dragon fruit, mango, grapefruit,&#xD;
                  etc.),strenuous exercises,or other factors may interfere with the absorption,&#xD;
                  distribution, metabolism, or excretion of drug within 14 days prior to screening.&#xD;
&#xD;
              10. Subjects who cannot tolerate standard meals (this clause only applies to subjects&#xD;
                  participating in food impact studies).&#xD;
&#xD;
              11. Presence of clinically significant abnormalities in ECG or QTcB&gt;450ms in males,or&#xD;
                  QTcB&gt;470ms in females.&#xD;
&#xD;
              12. Pregnancy or breastfeeding at screening and during the study.All female subjects&#xD;
                  of childbearing potential must have a negative urine pregnancy test at screening&#xD;
                  and during the trial.&#xD;
&#xD;
              13. Any clinically significant abnormality upon physical examination or in the&#xD;
                  clinical laboratory tests. History or presence of a clinically significant&#xD;
                  gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic,&#xD;
                  pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s)&#xD;
                  (but not limited to above disorders).&#xD;
&#xD;
              14. Presence of human immunodeficiency virus (HIV), viral hepatitis(including&#xD;
                  hepatitis C virus (HCV) or hepatitis B virus (HBV) ),treponema pallidum&#xD;
                  antibodies at screening.&#xD;
&#xD;
              15. Any acute illness or concomitant medication from screening to first dosing.&#xD;
&#xD;
              16. Have chocolate, any food or beverage that contains caffeine ,xanthine and alcohol&#xD;
                  within 24 hours prior to dosing.&#xD;
&#xD;
              17. Positive for urine drug screening or history of substance abuse for a period of 5&#xD;
                  consecutive years before screening.&#xD;
&#xD;
              18. As judged by the researcher, it is not suitable to join the clinical researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Friendship Hospital Affiliated to Capital Medical Universit</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

